Search clinical trials for: [68Ga]Ga-PentixaFor

Total 748 results

AstraZeneca

Completed

Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State

Type 2 Diabetes Mellitus
LG Life Sciences

Completed

Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)

Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)

Korea, Republic of
Beth Christian
Genentech, Inc.; Celgene

Active, not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Burkitt Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma and other conditions

United States
Novartis Pharmaceuticals

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis

Russian Federation
Peking University First Hospital
Xiangya Hospital of Central South University; Peking Union Medical College... and other collaborators

Unknown

A Study of Residual Curarization Incidence in China

Perioperative/Postoperative Complications | PORC (Postoperative Residual Curarization)

China
Montefiore Medical Center

Terminated

Comparing Mouth Rinses (and Chewing Gum) in Regard to Streptococcus Mutans Reduction

Dental Caries

United States
The Methodist Hospital Research Institute
Celgene Corporation

Terminated

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

Prostatic Neoplasms

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
UNICANCER
Cancer Research UK; National Cancer Institute, France; Servier; Pierre Fabre Medicament and other collaborators

Recruiting

Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10)

Biliary Tract Neoplasms

France, Belgium, United Kingdom
Uludag University

Completed

The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis (DINE)

Endometriosis

Turkey
Zagazig University

Unknown

PECS Block With Bupivacaine Vs Bupivacaine and Dexmedetomidine in Modified Radical Mastectomy

Anesthesia

Egypt
University Medicine Greifswald
SDI Limited

Completed

Fluoride Therapies on Hypersensitive Carious Lesions in Primary Teeth

Dentin Hypersensitivity | Active Dental Caries

Germany
Asthma Management Systems
Merck Sharp & Dohme LLC; West Penn Allegheny Health System

Completed

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

Asthma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Andrei Iagaru
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
Shanghai University of Traditional Chinese Medicine

Unknown

Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules.

Cough Variant Asthma

China
Teva Pharmaceuticals USA

Completed

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions

Healthy

Canada
University of Malaya

Recruiting

The Effect of Different Remineralizing Agents on White Spot Lesions and Dental Plaque During Orthodontic Retention

Orthodontic Appliance Complication

Malaysia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter Syndrome | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
University of Miami

Recruiting

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer (OCEAN)

Prostate Cancer | Prostate Adenocarcinoma | Hormone Sensitive Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Genentech, Inc.

Completed

A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)

Rheumatoid Arthritis

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Genentech, Inc.; Pharmacyclics LLC.

Recruiting

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma | Indolent Non-hodgkin Lymphoma | Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage II Nodal Marginal Zone Lymphoma | Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma | Ann Arbor... and other conditions

United States
Sanofi

Completed

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, United Kingdom, Austria
The Lymphoma Academic Research Organisation

Active, not recruiting

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (LyMa101)

Mantle Cell Lymphoma

France
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

Healthy Volunteer

United States
Miguel Santín
Institut d'Investigació Biomèdica de Bellvitge; Instituto de Salud Carlos III

Not yet recruiting

Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease

Latent Tuberculosis | Kidney Failure
Mahidol University

Recruiting

Bilateral Superficial Cervical Plexus Block in Thyroid/Parathyroid Surgery

Hyperparathyroidism | Benign Tumor of Thyroid

Thailand
University of Jordan

Completed

Sedation and Analgesia Using PFK Versus General Anesthesia in Urological Procedures

Urologic Diseases | Anesthesia

Jordan
National Cancer Institute (NCI)

Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Canada
University of Washington
Genentech, Inc.

Recruiting

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone...

United States
University of British Columbia

Unknown

Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy

Prostate Cancer

Canada
National Cancer Institute (NCI)

Terminated

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate

United States
University College, London
National University Hospital, Singapore; Singapore Clinical Research Institute...

Completed

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis (TRUNCATE-TB)

Tuberculosis, Pulmonary

Singapore, Uganda, Thailand, Indonesia, Philippines, India
National Cancer Institute (NCI)

Active, not recruiting

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology; Eastern Cooperative Oncology Group and other collaborators

Completed

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Australia, Peru, Puerto Rico
Xijing Hospital of Digestive Diseases

Recruiting

Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

the Eradication Rates of Helicobacter Pylori

China
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell Lymphoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States

Search clinical trials for: [68Ga]Ga-PentixaFor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations